- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Transcript
Recently, the FDA approved a sixth pegfilgrastim biosimilar (Fresenius Kabi’s Stimufend) and a fourth bevacizumab biosimilar (Celltrion Healthcare’s Vegzelma), the fourth and fifth oncology biosimilars to be approved in 2022 so far. What do these approvals tell you about the current status of the oncology biosimilar space?
Alvarnas: So, the key thing about biosimilars is when the concept first came, a lot of us were thinking, "What a quaint idea." And I think there was a lot of skepticism as to whether or not this would translate into something real. I think with the new approvals, what you see is this is something real—that we have biosimilars for a significant number of meaningful oncology products.
As we see multiple biosimilars enter into a competitive race with the originator molecule, then you get to a market-competitive model that can begin to address issues of drug pricing that can foster better stewardship as well as better engagement of clinicians as they think through their purchasing contracts, their supply chains, and clinical care pathways.
So, when we look at the portfolio of all the approved biosimilars, this constitutes something real. This constitutes a path forward toward embracing deeper models of value that don't compromise patient outcomes and don't compromise patient access by ensuring that we can be both value centered and yet extraordinary stewards of great care.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
